Central Cancer Registry Reporting Content IG, published by HL7 International / Public Health. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-central-cancer-registry-reporting-ig/ and changes regularly. See the Directory of published versions
<MedicationAdministration xmlns="http://hl7.org/fhir">
<id value="cancer-related-medication-administration-example"/>
<meta>
<profile
value="http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-administration"/>
</meta>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><b>Narrative</b></p><p><b>status:</b> completed</p><p><b>category:</b> Outpatient</p><p><b>medication:</b> rxnorm 1790099 doxorubicin hydrochloride 20 MG per 10 ML Injection</p><p><b>subject:</b> Amy Shaw</p><p><b>effective:</b> 2018-04-22</p><p><b>Performer:</b> Joseph Nichols</p><p><b>reasonReference:</b> Condition-primary-cancer-condition-breast</p><p><b>authoredOn:</b> 2018-04-12</p><p><b>note:</b> doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects.</p><p><b>Route:</b> SNOMED 47625008 Intravenous route (qualifier value)</p><p><b>Dose:</b> 105.96 mg</p></div>
</text>
<status value="completed"/>
<category>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/medication-admin-category"/>
<code value="outpatient"/>
</coding>
</category>
<medicationCodeableConcept>
<coding>
<system value="http://www.nlm.nih.gov/research/umls/rxnorm"/>
<code value="1790099"/>
<display value="10 ML doxorubicin hydrochloride 2 MG/ML Injection"/>
</coding>
</medicationCodeableConcept>
<subject>🔗
<reference value="Patient/example"/>
</subject>
<effectiveDateTime value="2018-04-22"/>
<performer>
<actor>🔗
<reference value="Practitioner/1"/>
</actor>
</performer>
<reasonReference>🔗
<reference value="Condition/primary-cancer-condition-breast"/>
</reasonReference>
<note>
<authorReference>🔗
<reference value="Practitioner/1"/>
</authorReference>
<time value="2018-04-22"/>
<text
value="doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects."/>
</note>
<dosage>
<route>
<coding>
<system value="http://snomed.info/sct"/>
<code value="47625008"/>
<display value="Intravenous route (qualifier value)"/>
</coding>
</route>
<dose>
<value value="105.96"/>
<unit value="mg"/>
<system value="http://unitsofmeasure.org"/>
<code value="mg"/>
</dose>
</dosage>
</MedicationAdministration>